Amenorrhea secondary prevention: Difference between revisions

	Amenorrhea Microchapters
Home
Patient Information Primary amenorrhea Secondary amenorrhea
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Amenorrhea from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Amenorrhea secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Amenorrhea secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Amenorrhea secondary prevention
CDC on Amenorrhea secondary prevention
Amenorrhea secondary prevention in the news
Blogs on Amenorrhea secondary prevention
Directions to Hospitals Treating Amenorrhea
Risk calculators and risk factors for Amenorrhea secondary prevention

VisualWikitext

Latest revision as of 20:22, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]

Overview

Effective measures for the secondary prevention of functional hypothalamic amenorrhea include oral contraceptive pills (OCPs), androgen therapy, recombinant insulin like growth factor 1 (IGF-1), recombinant leptin, bisphosphonates, and increasing calorie intake.

Secondary Prevention

Effective measures for the secondary prevention of functional hypothalamic amenorrhea include:

Oral contraceptive pills (OCPs)

Different studies have shown that OCP therapy can slow down the bone loss process in patients with exercise- and anorexia-associated amenorrhea. The detailed results are as following table:^[1]

Type of amenorrhea	Medicine		Dosage	Treatment duration	Bone mineral density (BMD) site	Outcome
Exercise-associated functional amenorrhea	Ethinyl estradiol		0.035 mg	12 months	Lumbar spine and femoral neck	Increased BMD in all sites^[2]
	Norethindrone Medroxyprogesterone		0.5-1.0 mg 10 mg	12 months	Lumbar spine and femoral neck	Increased BMD in all sites^[2]
	Ethinyl estradiol		0.03 or 0.02 mg	12 months	Lumbar spine	Increased BMD in all sites^[3]
	Desogestrel		0.15 mg	12 months	Lumbar spine	Increased BMD in all sites^[3]
	Ethinyl estradiol		0.030 mg	10 months	Lumbar spine and legs	Increase BMD in lumbar spine not in legs^[4]
	Levonorgestrel		0.150 mg	10 months	Lumbar spine and legs	Increase BMD in lumbar spine not in legs^[4]
	Ethinyl estradiol		0.05 mg	8 months	Lumbar spine and radius	Increase BMD in lumbar spine not in radius^[5]
	Cyproterone acetate		2 mg	8 months	Lumbar spine and radius	Increase BMD in lumbar spine not in radius^[5]
	Conjugated estrogen		0.0625 mg	24 months	Lumbar spine and femoral neck	Increased BMD in all sites^[6]
	Transdermal estradiol		0.05 mg	24 months	Lumbar spine and femoral neck	Increased BMD in all sites^[6]
	12 days	Estriol	1 mg	9.3 months	Lumbar spine, femoral neck, and trochanter	No change BMD in any sites^[7]
	12 days	Estradiol	2 mg
	10 days	Estriol	1 mg
		Estradiol	2 mg
		Norethisterone	1 mg
	6 days	Estriol	0.5 mg
	6 days	Estradiol	1 mg
	Premarin		0.625 mg	24 months	Lumbar spine, wrist, and foot	Increase BMD in lumbar spine, neither in wrist nor in foot^[8]
	Provera		10 mg	24 months	Lumbar spine, wrist, and foot
	Ethinyl estradiol		0.035 mg	10 months	Lumbar spine and femoral neck	Increase BMD in lumbar spine not in femoral neck^[9]
	Norgestimate		0.180–0.250 mg	10 months	Lumbar spine and femoral neck	Increase BMD in lumbar spine not in femoral neck^[9]
Anorexia-associated functional amenorrhea	Ethinyl estradiol		0.020–0.035 mg	12 months	Lumbar spine and femoral neck	No change BMD in any sites^[10]
	Norgestimate Norgestrel Norethindrone acetate Levonorgestrel		0.180–0.250 mg 0.5 mg 0.5-1.0 mg -	12 months	Lumbar spine and femoral neck	No change BMD in any sites^[10]
	Ethinyl estradiol		0.05 mg	12 months	Lumbar spine	No change BMD^[11]
	Norgestrel		0.5 mg	12 months	Lumbar spine	No change BMD^[11]
	Premarin		0.625 mg	18 months	Lumbar spine	No change BMD^[12]
	Provera		5 mg
	Ethinyl estradiol		0.035 mg
	Premarin		0.3–0.625 mg daily	4.3 years	Lumbar spine and femoral neck	Increased BMD in all sites^[13]
	Ethinyl estradiol		0.020 mg	12 months	Lumbar spine and femoral neck	No change BMD in any sites^[14]
	Levonorgestrel		0.1 mg
	Dihydroepiandrostendion (DHEA)		50 mg daily
	Recombinant IGF-1		30 mg/kg twice daily	9 months	Lumbar spine, femoral neck, and radius	No change BMD in any sites^[15]
	Ethinyl estradiol		0.035 mg
	Norethindrone		0.4 mg
	Ethinyl estradiol		0.035 mg	13 cycles	Lumbar spine and femoral neck	No significant change BMD in any sites^[16]
	Norgestimate		0.180–0.250 mg	13 cycles	Lumbar spine and femoral neck	No significant change BMD in any sites^[16]

Androgen therapy

Recent studies have shown that androgen therapy in the dose of 50, 100, or 200 mg of micronized DHEA daily may increase bone mineral density (BMD), and prevent osteoporotic fracture. However, there is no established long term study to prove this effect.^[14]

Recombinant insulin like growth factor 1 (IGF-1)

Recombinant insulin like growth factor 1 (IGF-1) (30 μg/kg−1 twice per day) along with OCP (0.035 mg ethinyl estradiol and 0.4 mg norethindrone) prevents fracture in hypothalamic amenorrhea (due to anorexia nervosa) by increasing bone mineral density (BMD).^[15]

Recombinant leptin

Recent studies have shown that administering recombinant leptin (0.08 mg/kg) subcutaneous daily for 2–3 months can lead to an increase in bone formation markers; and also decrease fracture risk through secondary prevention.^[17]

Bisphosphonates

In adolescent women with anorexia-induced amenorrhea, alendronate (10 mg) with calcium (1200 mg) and vitamin D (400 IU) for a year has been associated with significant improvement in bone loss. Therefore, bisphosphonates can be used as secondary prevention.^[18]
Doses of bisphosphonates for secondary prevention of functional amenorrhea are as follows:

Medicine	Dose	Treatment duration	Bone mineral density (BMD) site	Outcome
Etidronate	200 mg daily	3 months	Tibial midshaft	Non-significant increase in BMD in all sites^[19]
Calcium	600 mg daily
Vitamin D	1 μg daily
Risedronate	5 mg	9 months	Lumbar spine and femoral neck	Increase BMD in lumbar spine not in femoral neck^[20]
Calcium	1500 mg
Vitamin D	400 IU
Alendronate	10 mg	12 months	Lumbar spine and femoral neck	Non-significant increase in BMD in all sites^[21]
Calcium	1200 mg
Vitamin D	400 IU

Increasing calorie intake

Increasing daily calorie intake and weight gain in women with anorexia or exercise-induced amenorrhea can increase bone mineral density (BMD) and decrease long term complications associated with amenorrhea such as osteoporosis and fracture.^[22]^[23]^[24]

References

↑ Vescovi JD, Jamal SA, De Souza MJ (2008). "Strategies to reverse bone loss in women with functional hypothalamic amenorrhea: a systematic review of the literature". Osteoporos Int. 19 (4): 465–78. doi:10.1007/s00198-007-0518-6. PMID 18180975.
↑ Hergenroeder AC, Smith EO, Shypailo R, Jones LA, Klish WJ, Ellis K (1997). "Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months". Am. J. Obstet. Gynecol. 176 (5): 1017–25. PMID 9166162.
↑ Castelo-Branco C, Vicente JJ, Pons F, Martínez de Osaba MJ, Casals E, Vanrell JA (2001). "Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives". J Reprod Med. 46 (10): 875–9. PMID 11725730.
↑ Rickenlund A, Carlström K, Ekblom B, Brismar TB, Von Schoultz B, Hirschberg AL (2004). "Effects of oral contraceptives on body composition and physical performance in female athletes". J. Clin. Endocrinol. Metab. 89 (9): 4364–70. doi:10.1210/jc.2003-031334. PMID 15328063.
↑ De Crée C, Lewin R, Ostyn M (1988). "Suitability of cyproterone acetate in the treatment of osteoporosis associated with athletic amenorrhea". Int J Sports Med. 9 (3): 187–92. PMID 2970444.
↑ Cumming DC (1996). "Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy". Arch. Intern. Med. 156 (19): 2193–5. PMID 8885817.
↑ Gibson JH, Mitchell A, Reeve J, Harries MG (1999). "Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study". Osteoporos Int. 10 (4): 284–9. doi:10.1007/s001980050228. PMID 10692976.
↑ Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG, Hamilton L (2003). "Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study". Fertil. Steril. 80 (2): 398–404. PMID 12909505.
↑ Warren MP, Miller KK, Olson WH, Grinspoon SK, Friedman AJ (2005). "Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study". Contraception. 72 (3): 206–11. doi:10.1016/j.contraception.2005.03.007. PMID 16102557.
↑ Golden NH, Lanzkowsky L, Schebendach J, Palestro CJ, Jacobson MS, Shenker IR (2002). "The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa". J Pediatr Adolesc Gynecol. 15 (3): 135–43. PMID 12106749.
↑ Muñoz MT, Morandé G, García-Centenera JA, Hervás F, Pozo J, Argente J (2002). "The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa". Eur. J. Endocrinol. 146 (1): 45–50. PMID 11751066.
↑ Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC (1995). "The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa". J. Clin. Endocrinol. Metab. 80 (3): 898–904. doi:10.1210/jcem.80.3.7883849. PMID 7883849.
↑ Karlsson MK, Weigall SJ, Duan Y, Seeman E (2000). "Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa". J. Clin. Endocrinol. Metab. 85 (9): 3177–82. doi:10.1210/jcem.85.9.6796. PMID 10999805.
↑ ^14.0 ^14.1 Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS (2002). "Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial". J. Clin. Endocrinol. Metab. 87 (11): 4935–41. doi:10.1210/jc.2002-020545. PMID 12414853.
↑ ^15.0 ^15.1 Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A (2002). "Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa". J. Clin. Endocrinol. Metab. 87 (6): 2883–91. doi:10.1210/jcem.87.6.8574. PMID 12050268.
↑ Strokosch GR, Friedman AJ, Wu SC, Kamin M (2006). "Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study". J Adolesc Health. 39 (6): 819–27. doi:10.1016/j.jadohealth.2006.09.010. PMID 17116511.
↑ Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS (2004). "Recombinant human leptin in women with hypothalamic amenorrhea". N. Engl. J. Med. 351 (10): 987–97. doi:10.1056/NEJMoa040388. PMID 15342807.
↑ Golden NH, Iglesias EA, Jacobson MS, Carey D, Meyer W, Schebendach J, Hertz S, Shenker IR (2005). "Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial". J. Clin. Endocrinol. Metab. 90 (6): 3179–85. doi:10.1210/jc.2004-1659. PMID 15784715.
↑ Nakahara T, Nagai N, Tanaka M, Muranaga T, Kojima S, Nozoe S, Naruo T (2006). "The effects of bone therapy on tibial bone loss in young women with anorexia nervosa". Int J Eat Disord. 39 (1): 20–6. doi:10.1002/eat.20197. PMID 16231362.
↑ Miller KK, Grieco KA, Mulder J, Grinspoon S, Mickley D, Yehezkel R, Herzog DB, Klibanski A (2004). "Effects of risedronate on bone density in anorexia nervosa". J. Clin. Endocrinol. Metab. 89 (8): 3903–6. doi:10.1210/jc.2003-031885. PMID 15292325.
↑
↑ Viapiana O, Gatti D, Dalle Grave R, Todesco T, Rossini M, Braga V, Idolazzi L, Fracassi E, Adami S (2007). "Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight". Bone. 40 (4): 1073–7. doi:10.1016/j.bone.2006.11.015. PMID 17240212.
↑ Dominguez J, Goodman L, Sen Gupta S, Mayer L, Etu SF, Walsh BT, Wang J, Pierson R, Warren MP (2007). "Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses". Am. J. Clin. Nutr. 86 (1): 92–9. PMID 17616767.
↑ Fredericson M, Kent K (2005). "Normalization of bone density in a previously amenorrheic runner with osteoporosis". Med Sci Sports Exerc. 37 (9): 1481–6. PMID 16177598.

Template:WH Template:WS

[pmid18180975-1] Vescovi JD, Jamal SA, De Souza MJ (2008). "Strategies to reverse bone loss in women with functional hypothalamic amenorrhea: a systematic review of the literature". Osteoporos Int. 19 (4): 465–78. doi:10.1007/s00198-007-0518-6. PMID 18180975.

[pmid9166162-2] Hergenroeder AC, Smith EO, Shypailo R, Jones LA, Klish WJ, Ellis K (1997). "Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months". Am. J. Obstet. Gynecol. 176 (5): 1017–25. PMID 9166162.

[pmid11725730-3] Castelo-Branco C, Vicente JJ, Pons F, Martínez de Osaba MJ, Casals E, Vanrell JA (2001). "Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives". J Reprod Med. 46 (10): 875–9. PMID 11725730.

[pmid15328063-4] Rickenlund A, Carlström K, Ekblom B, Brismar TB, Von Schoultz B, Hirschberg AL (2004). "Effects of oral contraceptives on body composition and physical performance in female athletes". J. Clin. Endocrinol. Metab. 89 (9): 4364–70. doi:10.1210/jc.2003-031334. PMID 15328063.

[pmid2970444-5] De Crée C, Lewin R, Ostyn M (1988). "Suitability of cyproterone acetate in the treatment of osteoporosis associated with athletic amenorrhea". Int J Sports Med. 9 (3): 187–92. PMID 2970444.

[pmid8885817-6] Cumming DC (1996). "Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy". Arch. Intern. Med. 156 (19): 2193–5. PMID 8885817.

[pmid10692976-7] Gibson JH, Mitchell A, Reeve J, Harries MG (1999). "Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study". Osteoporos Int. 10 (4): 284–9. doi:10.1007/s001980050228. PMID 10692976.

[pmid12909505-8] Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG, Hamilton L (2003). "Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study". Fertil. Steril. 80 (2): 398–404. PMID 12909505.

[pmid16102557-9] Warren MP, Miller KK, Olson WH, Grinspoon SK, Friedman AJ (2005). "Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study". Contraception. 72 (3): 206–11. doi:10.1016/j.contraception.2005.03.007. PMID 16102557.

[pmid12106749-10] Golden NH, Lanzkowsky L, Schebendach J, Palestro CJ, Jacobson MS, Shenker IR (2002). "The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa". J Pediatr Adolesc Gynecol. 15 (3): 135–43. PMID 12106749.

[pmid11751066-11] Muñoz MT, Morandé G, García-Centenera JA, Hervás F, Pozo J, Argente J (2002). "The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa". Eur. J. Endocrinol. 146 (1): 45–50. PMID 11751066.

[pmid7883849-12] Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC (1995). "The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa". J. Clin. Endocrinol. Metab. 80 (3): 898–904. doi:10.1210/jcem.80.3.7883849. PMID 7883849.

[pmid10999805-13] Karlsson MK, Weigall SJ, Duan Y, Seeman E (2000). "Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa". J. Clin. Endocrinol. Metab. 85 (9): 3177–82. doi:10.1210/jcem.85.9.6796. PMID 10999805.

[pmid12414853-14] 14.0 ^14.1 Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS (2002). "Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial". J. Clin. Endocrinol. Metab. 87 (11): 4935–41. doi:10.1210/jc.2002-020545. PMID 12414853.

[pmid12050268-15] 15.0 ^15.1 Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A (2002). "Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa". J. Clin. Endocrinol. Metab. 87 (6): 2883–91. doi:10.1210/jcem.87.6.8574. PMID 12050268.

[pmid17116511-16] Strokosch GR, Friedman AJ, Wu SC, Kamin M (2006). "Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study". J Adolesc Health. 39 (6): 819–27. doi:10.1016/j.jadohealth.2006.09.010. PMID 17116511.

[pmid15342807-17] Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS (2004). "Recombinant human leptin in women with hypothalamic amenorrhea". N. Engl. J. Med. 351 (10): 987–97. doi:10.1056/NEJMoa040388. PMID 15342807.

[pmid157847152-18] Golden NH, Iglesias EA, Jacobson MS, Carey D, Meyer W, Schebendach J, Hertz S, Shenker IR (2005). "Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial". J. Clin. Endocrinol. Metab. 90 (6): 3179–85. doi:10.1210/jc.2004-1659. PMID 15784715.

[pmid16231362-19] Nakahara T, Nagai N, Tanaka M, Muranaga T, Kojima S, Nozoe S, Naruo T (2006). "The effects of bone therapy on tibial bone loss in young women with anorexia nervosa". Int J Eat Disord. 39 (1): 20–6. doi:10.1002/eat.20197. PMID 16231362.

[pmid15292325-20] Miller KK, Grieco KA, Mulder J, Grinspoon S, Mickley D, Yehezkel R, Herzog DB, Klibanski A (2004). "Effects of risedronate on bone density in anorexia nervosa". J. Clin. Endocrinol. Metab. 89 (8): 3903–6. doi:10.1210/jc.2003-031885. PMID 15292325.

[pmid15784715-21] ↑

[pmid17240212-22] Viapiana O, Gatti D, Dalle Grave R, Todesco T, Rossini M, Braga V, Idolazzi L, Fracassi E, Adami S (2007). "Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight". Bone. 40 (4): 1073–7. doi:10.1016/j.bone.2006.11.015. PMID 17240212.

[pmid17616767-23] Dominguez J, Goodman L, Sen Gupta S, Mayer L, Etu SF, Walsh BT, Wang J, Pierson R, Warren MP (2007). "Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses". Am. J. Clin. Nutr. 86 (1): 92–9. PMID 17616767.

[pmid16177598-24] Fredericson M, Kent K (2005). "Normalization of bone density in a previously amenorrheic runner with osteoporosis". Med Sci Sports Exerc. 37 (9): 1481–6. PMID 16177598.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Amenorrhea}}
+{{CMG}}; {{AE}}{{EG}}
-Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
+==Overview==
+Effective measures for the secondary prevention of functional [[hypothalamic]] amenorrhea include [[oral contraceptive pills]] (OCPs), [[androgen]] therapy, [[recombinant]] [[insulin-like growth factor-1|insulin like growth factor 1 (IGF-1)]], [[recombinant]] [[leptin]], [[bisphosphonates]], and increasing [[calorie]] intake.
-==Overview==
+==Secondary Prevention==
+Effective measures for the secondary prevention of functional [[hypothalamic]] amenorrhea include:
+===Oral contraceptive pills (OCPs)===
+*Different studies have shown that [[OCP]] therapy can slow down the [[bone loss]] process in patients with [[exercise]]- and [[anorexia]]-associated amenorrhea. The detailed results are as following table:<ref name="pmid18180975">{{cite journal |vauthors=Vescovi JD, Jamal SA, De Souza MJ |title=Strategies to reverse bone loss in women with functional hypothalamic amenorrhea: a systematic review of the literature |journal=Osteoporos Int |volume=19 |issue=4 |pages=465–78 |year=2008 |pmid=18180975 |doi=10.1007/s00198-007-0518-6 |url=}}</ref>
+{|
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Type of amenorrhea
+! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Medicine
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Dosage
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Treatment duration
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone mineral density (BMD) site
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Outcome
+|-
+! rowspan="21" style="background:#7d7d7d; color: #FFFFFF;" align="center" + |Exercise-associated<br>functional amenorrhea
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.035 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |12 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| rowspan="2" style="background:#F5F5F5;" + |Increased [[Bone mineral density|BMD]] in all sites<ref name="pmid9166162">{{cite journal |vauthors=Hergenroeder AC, Smith EO, Shypailo R, Jones LA, Klish WJ, Ellis K |title=Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months |journal=Am. J. Obstet. Gynecol. |volume=176 |issue=5 |pages=1017–25 |year=1997 |pmid=9166162 |doi= |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Norethindrone]]<br>[[Medroxyprogesterone]]
+| style="background:#F5F5F5;" align="center" + |0.5-1.0 mg<br>10 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.03 or 0.02 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |12 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]]
+| rowspan="2" style="background:#F5F5F5;" + |Increased [[Bone mineral density|BMD]] in all sites<ref name="pmid11725730">{{cite journal |vauthors=Castelo-Branco C, Vicente JJ, Pons F, Martínez de Osaba MJ, Casals E, Vanrell JA |title=Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives |journal=J Reprod Med |volume=46 |issue=10 |pages=875–9 |year=2001 |pmid=11725730 |doi= |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Desogestrel]]
+| style="background:#F5F5F5;" align="center" + |0.15 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.030 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |10 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]] and legs
+| rowspan="2" style="background:#F5F5F5;" + |Increase [[Bone mineral density|BMD]] in [[lumbar spine]] not in legs<ref name="pmid15328063">{{cite journal |vauthors=Rickenlund A, Carlström K, Ekblom B, Brismar TB, Von Schoultz B, Hirschberg AL |title=Effects of oral contraceptives on body composition and physical performance in female athletes |journal=J. Clin. Endocrinol. Metab. |volume=89 |issue=9 |pages=4364–70 |year=2004 |pmid=15328063 |doi=10.1210/jc.2003-031334 |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Levonorgestrel]]
+| style="background:#F5F5F5;" align="center" + |0.150 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.05 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |8 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[radius]]
+| rowspan="2" style="background:#F5F5F5;" + |Increase [[Bone mineral density|BMD]] in [[lumbar spine]] not in [[radius]]<ref name="pmid2970444">{{cite journal |vauthors=De Crée C, Lewin R, Ostyn M |title=Suitability of cyproterone acetate in the treatment of osteoporosis associated with athletic amenorrhea |journal=Int J Sports Med |volume=9 |issue=3 |pages=187–92 |year=1988 |pmid=2970444 |doi= |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Cyproterone acetate]]
+| style="background:#F5F5F5;" align="center" + |2 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |Conjugated [[estrogen]]
+| style="background:#F5F5F5;" align="center" + |0.0625 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |24 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| rowspan="2" style="background:#F5F5F5;" + |Increased [[Bone mineral density|BMD]] in all sites<ref name="pmid8885817">{{cite journal |vauthors=Cumming DC |title=Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy |journal=Arch. Intern. Med. |volume=156 |issue=19 |pages=2193–5 |year=1996 |pmid=8885817 |doi= |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Transdermal]] [[estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.05 mg
+|-
+| rowspan="2" style="background:#DCDCDC;" align="center" + |12 days
+| style="background:#DCDCDC;" align="center" + |[[Estriol]]
+| style="background:#F5F5F5;" align="center" + |1 mg
+| rowspan="7" style="background:#F5F5F5;" align="center" + |9.3 months
+| rowspan="7" style="background:#F5F5F5;" + |[[Lumbar spine]], [[femoral neck]], and [[trochanter]]
+| rowspan="7" style="background:#F5F5F5;" + |No change [[Bone mineral density|BMD]] in any sites<ref name="pmid10692976">{{cite journal |vauthors=Gibson JH, Mitchell A, Reeve J, Harries MG |title=Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study |journal=Osteoporos Int |volume=10 |issue=4 |pages=284–9 |year=1999 |pmid=10692976 |doi=10.1007/s001980050228 |url=}}</ref>
+|-
+| style="background:#DCDCDC;" align="center" + |[[Estradiol]]
+| style="background:#F5F5F5;" align="center" + |2 mg
+|-
+| rowspan="3" style="background:#DCDCDC;" align="center" + |10 days
+| style="background:#DCDCDC;" align="center" + |[[Estriol]]
+| style="background:#F5F5F5;" align="center" + |1 mg
+|-
+| style="background:#DCDCDC;" align="center" + |[[Estradiol]]
+| style="background:#F5F5F5;" align="center" + |2 mg
+|-
+| style="background:#DCDCDC;" align="center" + |[[Norethisterone]]
+| style="background:#F5F5F5;" align="center" + |1 mg
+|-
+| rowspan="2" style="background:#DCDCDC;" align="center" + |6 days
+| style="background:#DCDCDC;" align="center" + |[[Estriol]]
+| style="background:#F5F5F5;" align="center" + |0.5 mg
+|-
+| style="background:#DCDCDC;" align="center" + |[[Estradiol]]
+| style="background:#F5F5F5;" align="center" + |1 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Premarin]]
+| style="background:#F5F5F5;" align="center" + |0.625 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |24 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]], [[wrist]], and [[foot]]
+| rowspan="2" style="background:#F5F5F5;" + |Increase [[Bone mineral density|BMD]] in [[lumbar spine]], neither in [[wrist]] nor in [[foot]]<ref name="pmid12909505">{{cite journal |vauthors=Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG, Hamilton L |title=Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study |journal=Fertil. Steril. |volume=80 |issue=2 |pages=398–404 |year=2003 |pmid=12909505 |doi= |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Provera]]
+| style="background:#F5F5F5;" align="center" + |10 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.035 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |10 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| rowspan="2" style="background:#F5F5F5;" + |Increase [[Bone mineral density|BMD]] in [[lumbar spine]] not in [[femoral neck]]<ref name="pmid16102557">{{cite journal |vauthors=Warren MP, Miller KK, Olson WH, Grinspoon SK, Friedman AJ |title=Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study |journal=Contraception |volume=72 |issue=3 |pages=206–11 |year=2005 |pmid=16102557 |doi=10.1016/j.contraception.2005.03.007 |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Norgestimate]]
+| style="background:#F5F5F5;" align="center" + |0.180–0.250 mg
+|-
+! rowspan="16" style="background:#7d7d7d; color: #FFFFFF;" align="center" + |Anorexia-associated<br>functional amenorrhea
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.020–0.035 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |12 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| rowspan="2" style="background:#F5F5F5;" + |No change [[Bone mineral density|BMD]] in any sites<ref name="pmid12106749">{{cite journal |vauthors=Golden NH, Lanzkowsky L, Schebendach J, Palestro CJ, Jacobson MS, Shenker IR |title=The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa |journal=J Pediatr Adolesc Gynecol |volume=15 |issue=3 |pages=135–43 |year=2002 |pmid=12106749 |doi= |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Norgestimate]]<br>[[Norgestrel]]<br>[[Norethindrone acetate]]<br>[[Levonorgestrel]]
+| style="background:#F5F5F5;" align="center" + |0.180–0.250 mg<br>0.5 mg<br>0.5-1.0 mg<br>-
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.05 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |12 months
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]]
+| rowspan="2" style="background:#F5F5F5;" + |No change [[Bone mineral density|BMD]]<ref name="pmid11751066">{{cite journal |vauthors=Muñoz MT, Morandé G, García-Centenera JA, Hervás F, Pozo J, Argente J |title=The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa |journal=Eur. J. Endocrinol. |volume=146 |issue=1 |pages=45–50 |year=2002 |pmid=11751066 |doi= |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Norgestrel]]
+| style="background:#F5F5F5;" align="center" + |0.5 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Premarin]]
+| style="background:#F5F5F5;" align="center" + |0.625 mg
+| rowspan="3" style="background:#F5F5F5;" align="center" + |18 months
+| rowspan="3" style="background:#F5F5F5;" + |[[Lumbar spine]]
+| rowspan="3" style="background:#F5F5F5;" + |No change [[Bone mineral density|BMD]]<ref name="pmid7883849">{{cite journal |vauthors=Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC |title=The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa |journal=J. Clin. Endocrinol. Metab. |volume=80 |issue=3 |pages=898–904 |year=1995 |pmid=7883849 |doi=10.1210/jcem.80.3.7883849 |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Provera]]
+| style="background:#F5F5F5;" align="center" + |5 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.035 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Premarin]]
+| style="background:#F5F5F5;" align="center" + |0.3–0.625 mg daily
+| style="background:#F5F5F5;" align="center" + |4.3 years
+| style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| style="background:#F5F5F5;" + |Increased [[Bone mineral density|BMD]] in all sites<ref name="pmid10999805">{{cite journal |vauthors=Karlsson MK, Weigall SJ, Duan Y, Seeman E |title=Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa |journal=J. Clin. Endocrinol. Metab. |volume=85 |issue=9 |pages=3177–82 |year=2000 |pmid=10999805 |doi=10.1210/jcem.85.9.6796 |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.020 mg
+| rowspan="3" style="background:#F5F5F5;" align="center" + |12 months
+| rowspan="3" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| rowspan="3" style="background:#F5F5F5;" + |No change [[Bone mineral density|BMD]] in any sites<ref name="pmid12414853">{{cite journal |vauthors=Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS |title=Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial |journal=J. Clin. Endocrinol. Metab. |volume=87 |issue=11 |pages=4935–41 |year=2002 |pmid=12414853 |doi=10.1210/jc.2002-020545 |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Levonorgestrel]]
+| style="background:#F5F5F5;" align="center" + |0.1 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[DHEA|Dihydroepiandrostendion (DHEA)]]
+| style="background:#F5F5F5;" align="center" + |50 mg daily
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Recombinant]] [[Insulin-like growth factor 1|IGF-1]]
+| style="background:#F5F5F5;" align="center" + |30 mg/kg twice daily
+| rowspan="3" style="background:#F5F5F5;" align="center" + |9 months
+| rowspan="3" style="background:#F5F5F5;" + |[[Lumbar spine]], [[femoral neck]], and [[radius]]
+| rowspan="3" style="background:#F5F5F5;" + |No change [[Bone mineral density|BMD]] in any sites<ref name="pmid12050268">{{cite journal |vauthors=Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A |title=Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa |journal=J. Clin. Endocrinol. Metab. |volume=87 |issue=6 |pages=2883–91 |year=2002 |pmid=12050268 |doi=10.1210/jcem.87.6.8574 |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.035 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Norethindrone]]
+| style="background:#F5F5F5;" align="center" + |0.4 mg
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Ethinyl estradiol]]
+| style="background:#F5F5F5;" align="center" + |0.035 mg
+| rowspan="2" style="background:#F5F5F5;" align="center" + |13 cycles
+| rowspan="2" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| rowspan="2" style="background:#F5F5F5;" + |No significant change [[Bone mineral density|BMD]] in any sites<ref name="pmid17116511">{{cite journal |vauthors=Strokosch GR, Friedman AJ, Wu SC, Kamin M |title=Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study |journal=J Adolesc Health |volume=39 |issue=6 |pages=819–27 |year=2006 |pmid=17116511 |doi=10.1016/j.jadohealth.2006.09.010 |url=}}</ref>
+|-
+| colspan="2" style="background:#DCDCDC;" align="center" + |[[Norgestimate]]
+| style="background:#F5F5F5;" align="center" + |0.180–0.250 mg
+|}
+===Androgen therapy===
+* Recent studies have shown that androgen therapy in the dose of 50, 100, or 200 mg of micronized [[DHEA]] daily may increase [[Bone mineral density|bone mineral density (BMD)]], and prevent osteoporotic [[fracture]]. However, there is no established long term study to prove this effect.<ref name="pmid12414853">{{cite journal |vauthors=Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS |title=Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial |journal=J. Clin. Endocrinol. Metab. |volume=87 |issue=11 |pages=4935–41 |year=2002 |pmid=12414853 |doi=10.1210/jc.2002-020545 |url=}}</ref>
+===Recombinant insulin like growth factor 1 (IGF-1)===
+* [[Recombinant]] [[Insulin-like growth factor-1|insulin like growth factor 1 (IGF-1)]] (30 μg/kg−1 twice per day) along with OCP (0.035 mg [[ethinyl estradiol]] and 0.4 mg [[norethindrone]]) prevents [[fracture]] in [[hypothalamic]] amenorrhea (due to [[anorexia nervosa]]) by increasing [[Bone mineral density|bone mineral density (BMD)]].<ref name="pmid12050268">{{cite journal |vauthors=Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A |title=Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa |journal=J. Clin. Endocrinol. Metab. |volume=87 |issue=6 |pages=2883–91 |year=2002 |pmid=12050268 |doi=10.1210/jcem.87.6.8574 |url=}}</ref>
+===Recombinant leptin===
+* Recent studies have shown that administering [[recombinant]] [[leptin]] (0.08 mg/kg) [[subcutaneous]] daily for 2–3 months can lead to an increase in [[bone]] formation markers; and also decrease [[fracture]] risk through [[secondary prevention]].<ref name="pmid15342807">{{cite journal |vauthors=Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS |title=Recombinant human leptin in women with hypothalamic amenorrhea |journal=N. Engl. J. Med. |volume=351 |issue=10 |pages=987–97 |year=2004 |pmid=15342807 |doi=10.1056/NEJMoa040388 |url=}}</ref>
+===Bisphosphonates===
+*In [[adolescent]] women with [[anorexia]]-induced amenorrhea, [[alendronate]] (10 mg) with [[calcium]] (1200 mg) and [[vitamin D]] (400 IU) for a year has been associated with significant improvement in [[bone loss]]. Therefore, [[bisphosphonates]] can be used as [[secondary prevention]].<ref name="pmid157847152">{{cite journal |vauthors=Golden NH, Iglesias EA, Jacobson MS, Carey D, Meyer W, Schebendach J, Hertz S, Shenker IR |title=Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial |journal=J. Clin. Endocrinol. Metab. |volume=90 |issue=6 |pages=3179–85 |year=2005 |pmid=15784715 |doi=10.1210/jc.2004-1659 |url=}}</ref>
+*Doses of [[bisphosphonates]] for secondary prevention of functional amenorrhea are as follows:
+{|
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Medicine
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Dose
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Treatment duration
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone mineral density (BMD) site
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Outcome
+|-
+| style="background:#DCDCDC;" align="center" + |[[Etidronate]]
+| style="background:#F5F5F5;" align="center" + |200 mg daily
+| rowspan="3" style="background:#F5F5F5;" align="center" + |3 months
+| rowspan="3" style="background:#F5F5F5;" + |[[Tibial]] midshaft
+| rowspan="3" style="background:#F5F5F5;" + |Non-significant increase in [[Bone mineral density|BMD]] in all sites<ref name="pmid16231362">{{cite journal |vauthors=Nakahara T, Nagai N, Tanaka M, Muranaga T, Kojima S, Nozoe S, Naruo T |title=The effects of bone therapy on tibial bone loss in young women with anorexia nervosa |journal=Int J Eat Disord |volume=39 |issue=1 |pages=20–6 |year=2006 |pmid=16231362 |doi=10.1002/eat.20197 |url=}}</ref>
+|-
+| style="background:#DCDCDC;" align="center" + |[[Calcium]]
+| style="background:#F5F5F5;" align="center" + |600 mg daily
+|-
+| style="background:#DCDCDC;" align="center" + |[[Vitamin D]]
+| style="background:#F5F5F5;" align="center" + |1 μg daily
+|-
+| style="background:#DCDCDC;" align="center" + |[[Risedronate]]
+| style="background:#F5F5F5;" align="center" + |5 mg
+| rowspan="3" style="background:#F5F5F5;" align="center" + |9 months
+| rowspan="3" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| rowspan="3" style="background:#F5F5F5;" + |Increase [[Bone mineral density|BMD]] in [[lumbar spine]] not in [[femoral neck]]<ref name="pmid15292325">{{cite journal |vauthors=Miller KK, Grieco KA, Mulder J, Grinspoon S, Mickley D, Yehezkel R, Herzog DB, Klibanski A |title=Effects of risedronate on bone density in anorexia nervosa |journal=J. Clin. Endocrinol. Metab. |volume=89 |issue=8 |pages=3903–6 |year=2004 |pmid=15292325 |doi=10.1210/jc.2003-031885 |url=}}</ref>
+|-
+| style="background:#DCDCDC;" align="center" + |[[Calcium]]
+| style="background:#F5F5F5;" align="center" + |1500 mg
+|-
+| style="background:#DCDCDC;" align="center" + |[[Vitamin D]]
+| style="background:#F5F5F5;" align="center" + |400 IU
+|-
+| style="background:#DCDCDC;" align="center" + |[[Alendronate]]
+| style="background:#F5F5F5;" align="center" + |10 mg
+| rowspan="3" style="background:#F5F5F5;" align="center" + |12 months
+| rowspan="3" style="background:#F5F5F5;" + |[[Lumbar spine]] and [[femoral neck]]
+| rowspan="3" style="background:#F5F5F5;" + |Non-significant increase in [[Bone mineral density|BMD]] in all sites<ref name="pmid15784715" />
+|-
+| style="background:#DCDCDC;" align="center" + |[[Calcium]]
+| style="background:#F5F5F5;" align="center" + |1200 mg
+|-
+| style="background:#DCDCDC;" align="center" + |[[Vitamin D]]
+| style="background:#F5F5F5;" align="center" + |400 IU
+|}
+===Increasing calorie intake===
+* Increasing daily calorie intake and weight gain in women with [[anorexia]] or [[exercise]]-induced amenorrhea can increase [[bone mineral density|bone mineral density (BMD)]] and decrease long term complications associated with amenorrhea such as [[osteoporosis]] and [[fracture]].<ref name="pmid17240212">{{cite journal |vauthors=Viapiana O, Gatti D, Dalle Grave R, Todesco T, Rossini M, Braga V, Idolazzi L, Fracassi E, Adami S |title=Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight |journal=Bone |volume=40 |issue=4 |pages=1073–7 |year=2007 |pmid=17240212 |doi=10.1016/j.bone.2006.11.015 |url=}}</ref><ref name="pmid17616767">{{cite journal |vauthors=Dominguez J, Goodman L, Sen Gupta S, Mayer L, Etu SF, Walsh BT, Wang J, Pierson R, Warren MP |title=Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses |journal=Am. J. Clin. Nutr. |volume=86 |issue=1 |pages=92–9 |year=2007 |pmid=17616767 |doi= |url=}}</ref><ref name="pmid16177598">{{cite journal |vauthors=Fredericson M, Kent K |title=Normalization of bone density in a previously amenorrheic runner with osteoporosis |journal=Med Sci Sports Exerc |volume=37 |issue=9 |pages=1481–6 |year=2005 |pmid=16177598 |doi= |url=}}</ref>
 ==References==
 {{Reflist|2}}
-[[Category:Needs content]]
 {{WH}}
 {{WS}}
+[[Category:Medicine]]
+[[Category:Endocrinology]]
+[[Category:Up-To-Date]]
+[[Category:Gynecology]]
+[[Category:Obstetrics]]